Abstract summary 

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Recent evidence suggests that gamma-aminobutyric acid B (GABA) receptor-mediated inhibition is a major contributor to AD pathobiology, and GABA receptors have been hypothesized to be a potential target for AD treatment. The aim of this study is to determine how GABA regulation alters cognitive function and brain activity in an AD mouse model. Early, middle and late stage (8-23 months) amyloid precursor protein (APP) and presenilin 1 (PS1) transgenic mice were used for the study. The GABA agonist baclofen (1 and 2.5 mg/kg, i. p.) and the antagonist phaclofen (0.5 mg/kg, i. p.) were used. Primarily, we found that GABA activation was able to improve spatial and/or working memory performance in early and late stage AD animals. In addition, GABA activation and inhibition could regulate global and local EEG oscillations in AD animals, with activation mainly regulating low-frequency activity (delta-theta bands) and inhibition mainly regulating mid- and high-frequency activity (alpha-gamma bands), although the regulated magnitude at some frequencies was reduced in AD. The cognitive improvements in AD animals may be explained by the reduced EEG activity in the theta frequency band (2-4 Hz). This study provides evidence for a potential therapeutic effect of baclofen in the elderly AD brain and for GABA receptor-mediated inhibition as a potential therapeutic target for AD.

Authors & Co-authors:  Yuan Zhou Song Zhang Zhang Ren Chen Fu

Study Outcome 

Source Link: Visit source